• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

结直肠癌肝转移的分子和免疫组化标志物及其预后和预测意义。

Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma.

机构信息

Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, Italy.

Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Francesco Sforza 35, 20122 Milan, Italy.

出版信息

Int J Mol Sci. 2018 Oct 3;19(10):3014. doi: 10.3390/ijms19103014.

DOI:10.3390/ijms19103014
PMID:30282914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6213422/
Abstract

Despite the significant recent achievements in the diagnosis and treatment of colorectal cancer (CRC), the prognosis of these patients has currently plateaued. During the past few years, the opportunity to consider multiple treatment modalities (including surgery and other locoregional treatments, systemic therapy, and targeted therapy) led to the research of novel prognostic and predictive biomarkers in CRC liver metastases (CRCLM) patients. In this review, we seek to describe the current state of knowledge of CRCLM biomarkers and to outline impending clinical perspectives, in particular focusing on the cutting-edge tools available for their characterization.

摘要

尽管近年来在结直肠癌（CRC）的诊断和治疗方面取得了重大进展，但这些患者的预后目前已趋于稳定。在过去的几年中，考虑多种治疗方式（包括手术和其他局部区域治疗、全身治疗和靶向治疗）的机会促使人们对结直肠癌肝转移（CRCLM）患者的新型预后和预测生物标志物进行了研究。在这篇综述中，我们旨在描述 CRCLM 生物标志物的现有知识状况，并概述即将出现的临床前景，特别是侧重于用于其特征描述的前沿工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/49d42ec69dae/ijms-19-03014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/56d91204b2a8/ijms-19-03014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/f5f67d7282a0/ijms-19-03014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/fde893638af5/ijms-19-03014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/344cbea5990f/ijms-19-03014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/49d42ec69dae/ijms-19-03014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/56d91204b2a8/ijms-19-03014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/f5f67d7282a0/ijms-19-03014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/fde893638af5/ijms-19-03014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/344cbea5990f/ijms-19-03014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ca/6213422/49d42ec69dae/ijms-19-03014-g005.jpg

相似文献

1
Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma.结直肠癌肝转移的分子和免疫组化标志物及其预后和预测意义。
Int J Mol Sci. 2018 Oct 3;19(10):3014. doi: 10.3390/ijms19103014.
2
Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer.结直肠癌患者原发性肿瘤及配对肝转移灶中微小RNA表达谱的差异分析
Oncotarget. 2017 May 30;8(22):35783-35791. doi: 10.18632/oncotarget.16206.
3
Long non-coding RNAs: novel prognostic biomarkers for liver metastases in patients with early stage colorectal cancer.长链非编码RNA：早期结直肠癌患者肝转移的新型预后生物标志物。
Oncotarget. 2016 Aug 2;7(31):50428-50436. doi: 10.18632/oncotarget.10416.
4
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.表皮生长因子受体（EGFR）和前列腺素内过氧化物合酶2（PTGS2）是接受手术切除的结直肠癌肝转移患者的预后生物标志物。
Br J Cancer. 2014 Aug 12;111(4):749-55. doi: 10.1038/bjc.2014.354. Epub 2014 Jul 1.
5
Prognostic value of β1 integrin expression in colorectal liver metastases.β1整合素表达在结直肠癌肝转移中的预后价值
Int J Clin Exp Pathol. 2013 Dec 15;7(1):288-300. eCollection 2014.
6
Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker.原发性结直肠癌和肝转移的比较分析鉴定 LEF1 为预后生物标志物。
PLoS One. 2011 Feb 24;6(2):e16636. doi: 10.1371/journal.pone.0016636.
7
Stromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases.热休克蛋白27的基质表达与结直肠癌肺转移患者较差的临床结局相关。
PLoS One. 2015 Mar 20;10(3):e0120724. doi: 10.1371/journal.pone.0120724. eCollection 2015.
8
Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.结直肠癌侵袭前沿中 ZEB2 的过表达是一个独立的预后标志物，并调节体外肿瘤侵袭。
Clin Cancer Res. 2011 Dec 15;17(24):7654-63. doi: 10.1158/1078-0432.CCR-10-2816. Epub 2011 Oct 31.
9
Aberrant expression of sphingosine-1-phosphate receptor 1 correlates with metachronous liver metastasis and poor prognosis in colorectal cancer.鞘氨醇-1-磷酸受体1的异常表达与结直肠癌的异时性肝转移及不良预后相关。
Tumour Biol. 2014 Oct;35(10):9743-50. doi: 10.1007/s13277-014-2267-4. Epub 2014 Jun 28.
10
A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.结直肠癌肝转移和肺转移及其相应宿主组织的综合微小RNA表达谱及其对生存的预后影响。
Int J Mol Sci. 2016 Oct 21;17(10):1755. doi: 10.3390/ijms17101755.

引用本文的文献

1
Effect of Missense Variants on Its Tumor-Suppressive Function.错义变体对其肿瘤抑制功能的影响。
J Korean Med Sci. 2025 Jul 14;40(27):e146. doi: 10.3346/jkms.2025.40.e146.
2
Metabolomics- and Proteomics-Based Disease Diagnostic Classifier Model for the Prediction and Diagnosis of Colorectal Carcinoma.基于代谢组学和蛋白质组学的结直肠癌预测与诊断疾病诊断分类模型
J Proteome Res. 2025 Apr 4;24(4):2096-2111. doi: 10.1021/acs.jproteome.5c00010. Epub 2025 Mar 19.
3
Chloride Intracellular Channel Protein 1 Expression and Angiogenic Profile of Liver Metastasis of Digestive Origin.

本文引用的文献

1
Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.结直肠癌肿瘤演进过程中的基因组改变：全外显子组测序对原发肿瘤和同步肝转移瘤的差异追踪。
BMC Cancer. 2018 Jul 20;18(1):752. doi: 10.1186/s12885-018-4639-4.
2
GADD45B as a Prognostic and Predictive Biomarker in Stage II Colorectal Cancer.GADD45B作为II期结直肠癌的预后和预测生物标志物
Genes (Basel). 2018 Jul 19;9(7):361. doi: 10.3390/genes9070361.
3
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
氯化物细胞内通道蛋白1在消化源性肝转移中的表达及血管生成特征
Curr Issues Mol Biol. 2023 Feb 6;45(2):1396-1406. doi: 10.3390/cimb45020091.
4
Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives.结直肠癌筛查与诊断中的多组学方法：最新进展与未来展望
Cancers (Basel). 2022 Nov 11;14(22):5545. doi: 10.3390/cancers14225545.
5
Diagnostic and therapeutic biomarkers in colorectal cancer: a review.结直肠癌的诊断和治疗生物标志物：综述
Am J Cancer Res. 2022 Feb 15;12(2):661-680. eCollection 2022.
6
Identification of Target PTEN-Based miR-425 and miR-576 as Potential Diagnostic and Immunotherapeutic Biomarkers of Colorectal Cancer With Liver Metastasis.基于靶标PTEN的miR-425和miR-576作为结直肠癌肝转移潜在诊断和免疫治疗生物标志物的鉴定。
Front Oncol. 2021 Aug 19;11:657984. doi: 10.3389/fonc.2021.657984. eCollection 2021.
7
Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer.核心昼夜节律时钟蛋白作为结直肠癌进展的生物标志物
Biomedicines. 2021 Aug 6;9(8):967. doi: 10.3390/biomedicines9080967.
8
Liver Metastatic Colorectal Tumor Cells Change Their Phenotype During Consecutive Passages on Chick Embryo Chorioallantoic Membrane: Lessons from the Lab to the Clinic.鸡胚绒毛尿囊膜连续传代过程中肝转移结直肠肿瘤细胞改变其表型：从实验室到临床的经验教训。
In Vivo. 2021 Sep-Oct;35(5):2711-2718. doi: 10.21873/invivo.12555.
9
Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review.结直肠癌患者的远处转移——我们是否有新的预测临床病理和分子生物标志物？全面综述。
Int J Mol Sci. 2020 Jul 24;21(15):5255. doi: 10.3390/ijms21155255.
10
Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications.胰岛素样生长因子 2 (IGF2) 信号在结直肠癌中的作用——从基础研究到潜在的临床应用。
Int J Mol Sci. 2019 Oct 3;20(19):4915. doi: 10.3390/ijms20194915.
KRAS、BRAF、PI3K和TP53基因突变分析对可切除和不可切除结直肠癌肝转移的临床意义及预后相关性：当前证据的系统评价
Surg Oncol. 2018 Jun;27(2):280-288. doi: 10.1016/j.suronc.2018.05.012. Epub 2018 May 8.
4
Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC.帕尼单抗治疗转移性结直肠癌，包括野生型 RAS、KRAS 和 NRAS mCRC。
Future Oncol. 2018 Oct;14(24):2437-2459. doi: 10.2217/fon-2017-0711. Epub 2018 May 8.
5
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?结直肠癌患者接受抗 EGFR 治疗后肝转移中出现 KRAS 突变：我们是否意识到肿瘤异质性的治疗影响？
Cancer Biol Ther. 2018 Aug 3;19(8):659-663. doi: 10.1080/15384047.2018.1450117. Epub 2018 Apr 13.
6
Biomarkers in colorectal liver metastases.结直肠癌肝转移的生物标志物。
Br J Surg. 2018 May;105(6):618-627. doi: 10.1002/bjs.10834. Epub 2018 Mar 26.
7
MicroRNA-192-5p is a predictive biomarker of survival for Stage IIIB colon cancer patients.微小RNA-192-5p是IIIB期结肠癌患者生存的预测性生物标志物。
Jpn J Clin Oncol. 2018 Jul 1;48(7):619-624. doi: 10.1093/jjco/hyy019.
8
and Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.靶向叶酸受体-α的抗体药物偶联物 IMGN853 联合 DM4 治疗生物侵袭性子宫内膜癌的活性。
Mol Cancer Ther. 2018 May;17(5):1003-1011. doi: 10.1158/1535-7163.MCT-17-0930. Epub 2018 Feb 13.
9
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).抗 EGFR 而非抗 VEGF 治疗的 mCRC 中，侧别和 TP53 突变影响 OS - KRAS 登记处的 AGMT（药物治疗肿瘤学工作组）分析。
BMC Cancer. 2018 Jan 3;18(1):11. doi: 10.1186/s12885-017-3955-4.
10
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers.构建高通量筛选平台以评估乳腺癌中HER2基因扩增的异质性。
J Vis Exp. 2017 Dec 5(130):56686. doi: 10.3791/56686.